This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
World Health Organization (WHO). Information Note Nitrosamine impurities [displayed 24 September 2020]. Available athttps://www.who.int/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/World Health Organization (WHO)Available athttps://www.who.int/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/Search in Google Scholar
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [displayed 7 March 2021]. p. 6. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdfInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)p. 6. Available athttps://www.ema.europa.eu/en/documents/scientific-guideline/ch-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdfSearch in Google Scholar
European Medicines Agency (EMA). Procedure under Article 5(3) of Regulation EC (No) 726/2004. Nitrosamine impurities in human medicinal products [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdfEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdfSearch in Google Scholar
European Medicines Agency (EMA). Lessons learnt from presence of N-nitrosamine impurities in sartan medicines [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdfEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/documents/report/essons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdfSearch in Google Scholar
Šulc M, Hodek P, Stiborová M. The binding affinity of c a r c in o gen i c N- nit r o so dim et h y l a mine a n d N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. Gen Physiol Biophys 2010;29:175-85. doi: 10.4149/gpb_2010_02_175ŠulcMHodekPStiborováMThe binding affinity of c a r c in o gen i c N- nit r o so dim et h y l a mine a n d N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation2010291758510.4149/gpb_2010_02_17520577029Open DOISearch in Google Scholar
European Medicines Agency (EMA). Assessment report Referral under Article 31 of Directive 2001/83/EC [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/documents/variation-report/sartans-article-31-referral-chmp-assessment-report_en.pdfEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/documents/variation-report/sartans-article-31-referral-chmp-assessment-report_en.pdfSearch in Google Scholar
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [displayed 7 March 2021]. Available athttps://eur-lex.europa.eu/eli/dir/2001/83/Available athttps://eur-lex.europa.eu/eli/dir/2001/83/Search in Google Scholar
European Medicines Agency (EMA). EU inspection finds Zhejiang Huahai site non-compliant for manufacture of valsartan: EMA and national authorities considering impact on other active substances produced at the site [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/news/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan-ema-nationalEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/news/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan-ema-nationalSearch in Google Scholar
European Medicines Agency (EMA). Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impuritiesEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impuritiesSearch in Google Scholar
European Medicines Agency (EMA). Nitrosamine impurities [displayed 24 September 2020]. Available athttps://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities#metformin-containing-medicines-sectionEuropean Medicines Agency (EMA)Available athttps://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities#metformin-containing-medicines-sectionSearch in Google Scholar
World Health Organization (WHO). Guidelines for Drinking-water Quality. 3rd ed. Vol 1, Incorporating first and second addenda. Geneva; WHO; 2008.World Health Organization (WHO)GenevaWHO2008Search in Google Scholar
Krul CAM, Zeilmaker MJ, Schothorst RC, Havenaar R. Intragastric formation and modulation of N-nitrosodimethylamine in a dynamic in vitro gastrointestinal model under human physiological conditions. Food Chem Toxicol 2004;42:51-63. doi: 10.1016/j.fct.2003.08.005KrulCAMZeilmakerMJSchothorstRCHavenaarRIntragastric formation and modulation of N-nitrosodimethylamine in a dynamic in vitro gastrointestinal model under human physiological conditions200442516310.1016/j.fct.2003.08.00514630130Open DOISearch in Google Scholar
Song P, Wu L, Guan W. Dietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: A meta-analysis. Nutrients 2015;7:9872-95. doi: 10.3390/nu7125505SongPWuLGuanWDietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: A meta-analysis2015798729510.3390/nu7125505469005726633477Open DOISearch in Google Scholar
Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Medicinal products database [displayed 24 September 2020]. Available athttps://www.halmed.hr/Lijekovi/Baza-lijekova/Available athttps://www.halmed.hr/Lijekovi/Baza-lijekova/Search in Google Scholar
Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Obavijest o nestašici lijekova s djelatnom tvari ranitidin [Notice of shortage of drugs with the active substance ranitidine, in Croatian] [displayed 24 September 2020]. Available athttps://www.halmed.hr/Novosti-i-edukacije/Novosti/2019/Obavijest-o-nestasici-lijekova-s-djelatnom-tvari-ranitidin-/2239Agency for Medicinal Products and Medical Devices of Croatia (HALMED)Available athttps://www.halmed.hr/Novosti-i-edukacije/Novosti/2019/Obavijest-o-nestasici-lijekova-s-djelatnom-tvari-ranitidin-/2239Search in Google Scholar
Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Obustava izvršenja odobrenja za stavljanje u promet lijekova koji sadrže djelatnu tvar ranitidin u Europskoj uniji [Suspension of the marketing authorization for medicinal products containing the active substance ranitidine in the European Union, in Croatian] [displayed 24 September 2020]. Available athttps://www.halmed.hr/Novosti-i-edukacije/Novosti/2020/Obustava-izvrsenja-odobrenja-za-stavljanje-u-promet-lijekova-koji-sadrze-djelatnu-tvar-ranitidin-u-Europskoj-uniji/2360/Agency for Medicinal Products and Medical Devices of Croatia (HALMED)Available athttps://www.halmed.hr/Novosti-i-edukacije/Novosti/2020/Obustava-izvrsenja-odobrenja-za-stavljanje-u-promet-lijekova-koji-sadrze-djelatnu-tvar-ranitidin-u-Europskoj-uniji/2360/Search in Google Scholar
Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2018. [Report on medicinal product utilization in the Republic of Croatia in 2018, in Croatian] [displayed 24 September 2020]. Available athttps://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2018/Agency for Medicinal Products and Medical Devices of Croatia (HALMED)Available athttps://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2018/Search in Google Scholar
Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2019. [Report on medicinal product utilization in the Republic of Croatia in 2019, in Croatian] [displayed 24 September 2020]. Available athttps://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2019/Agency for Medicinal Products and Medical Devices of Croatia (HALMED)Available athttps://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2019/Search in Google Scholar